The U.S. Food and Drug Administration (FDA) has formally approved an expanded indication for Merck & Co.’s 21-valent pneumococcal conjugate vaccine, Capvaxive. Executed on June 18, 2026, the regulatory clearance authorizes the administration of the vaccine to high-risk children and adolescents aged 2 through 17 years who have previously completed a primary pediatric pneumococcal vaccination series and present with one or more chronic medical comorbidities.
Following this milestone, Capvaxive establishes itself as the only Pneumococcal Conjugate Vaccine (PCV) specifically indicated and clinically studied within the United States for this vulnerable pediatric sub-population.
The documented inclusion of eight adult-predominant invasive serotypes, non-inferiority endpoints from the Phase III STRIDE-13 matrix, and corresponding reactive safety profiles feature:
-
Serotype Inclusion Mechanics and High-Risk Patient Stratification Criteria:
-
Addressing Serotype Replacement: Capvaxive was fundamentally engineered for adult demographics to optimize coverage against Streptococcus pneumoniae serotypes predominantly driving invasive pneumococcal disease (IPD). The formulation holds a unique profile by including eight exclusive adult-predominant serotypes—15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B—which are entirely absent from all other approved alternative pneumococcal vaccines. The pediatric expansion targets serotype replacement gaps emerging after the close of routine childhood primary PCV series.
-
Target Cohort Demographics: The pediatric label expansion is strictly sequestered to patients aged 2–17 who completed their primary baseline pneumococcal series at least eight weeks prior and present with specific underlying chronic diagnoses. Eligible risk criteria encompass diabetes, chronic cardiac disease, chronic kidney disease, chronic liver disease, or chronic pulmonary disease. Dr. Rotem Lapidot, Chief of Pediatric Infectious Diseases at Rambam Health Care Campus, emphasized that these compromised cohorts experience substantially heightened baseline risks for severe manifestations, including pneumonia, meningitis, and systemic bloodstream infections.
-
-
Immunogenicity Efficacy Displacements From the STRIDE-13 Phase III Framework:
-
Clinical Protocol Architecture: The expanded regulatory clearance is anchored by endpoints derived from the Phase III STRIDE-13 clinical trial, a randomized, double-blind, active comparator-controlled multi-center study enrolling 874 pediatric participants presenting with prespecified chronic conditions. Subjects were randomized in a tight 3:2 allocation matrix to receive a single dose of either investigational Capvaxive (n=527) or the standard 23-valent pneumococcal polysaccharide vaccine, PPSV23 (n=347).
-
Non-Inferiority Verification: Capvaxive successfully demonstrated non-inferiority relative to the PPSV23 comparator across all 12 mutually shared serotypes. Crucially, for the nine serotypes unique to Merck’s formulation, Capvaxive elicited statistically significantly greater opsonophagocytic activity geometric mean titers (OPA GMTs) compared against the active control arm. A subsequent post-hoc analysis further established verified non-inferiority for serotype 15B due to its direct structural cross-reactivity with the vaccine-contained serotype 15C.
-
-
Biocompatibility Safety Indices and Documented Adverse Events:
-
The structural safety profile of Capvaxive tracked comparably to the established reference baseline of PPSV23. The most frequently logged solicited local and systemic adverse reactions within the 2-to-17 age group featured injection-site pain (67.7%), localized injection-site erythema (24.3%), systemic fatigue (20.1%), and injection-site swelling (18.8%). The recorded symptoms presented a median duration of two days, with a significant majority resolving completely within three days or fewer.
-
The cumulative incidence rate of serious adverse events (SAEs) monitored through a 6-month post-vaccination window settled at 5.5% within the Capvaxive cohort versus 7.2% within the comparative PPSV23 cohort, yielding zero notable pathological patterns or statistical imbalances between the active study arms.
-